This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Oka, R. K Articles by Cooke, J. P Search for Related Content PubMed PubMed Citation Articles by Oka, R. K Articles by Cooke, J. P Social Bookmarking                         What's this?

A pilot study of l-arginine supplementation on functional capacity in peripheral arterial disease

School of Nursing, University of California San Francisco, San Francisco, California, USA, roberta.oka{at}nursing.ucsf.edu

Andrzej Szuba

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA

John C Giacomini

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA

John P Cooke

Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA

Peripheral arterial disease (PAD) impairs walking capacity and is often associated with a profound endothelial vasodilator dysfunction, characterized by reduced bioactivity and/or synthesis of endothelium-derived nitric oxide (NO). Previous studies have suggested that dietary supplementation of L-arginine, the precursor of NO, improves endothelium-dependent vasodilation, limb blood flow and walking distance. However, these studies have been small, and have used large intravenous doses of L-arginine. The optimal dose of L-arginine has not been determined. Accordingly, this pilot study was conducted to establish the lowest effective oral dose of L-arginine to improve walking distance in preparation for the definitive study. Patients with PAD and intermittent claudication (n = 80) participated in this study. Eligibility criteria included: (1) ankle-brachial index (ABI) at rest 0.90; (2) post-exercise reduction in ABI 25%; and (3) difference in absolute claudication distance of 25% between two consecutive treadmill tests. Treadmill testing was performed using the Skinner-Gardner protocol and community-based walking was assessed using the walking impairment questionnaire. Patients were randomly assigned to oral doses of 0, 3, 6 or 9 g of L-arginine daily in three divided doses for 12 weeks. Treadmill testing was performed prior to administration of the study drug and again after 12 weeks of treatment. The study drug was well tolerated, with no significant adverse effects of L-arginine therapy. The safety laboratory studies were unremarkable, except for a statistically significant reduction in hematocrit in the L-arginine-treated groups. There was no significant difference observed in absolute claudication distance between the groups. However, a trend was observed for a greater increase in walking distance in the group treated with 3 g L-arginine daily, and there was a trend for an improvement in walking speed in patients treated with L-arginine. This pilot study provided data for safety, for power calculation and for dosing for the larger definitive trial that is now underway.

Key Words: functional capacity • l-arginine • vascular disease

Vascular Medicine, Vol. 10, No. 4, 265-274 (2005)
DOI: 10.1191/1358863x05vm637oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Wilson, E. Kimura, R. K. Harada, N. Nair, B. Narasimhan, X.-Y. Meng, F. Zhang, K. R. Beck, J. W. Olin, E. T. Fung, et al. {beta}2-Microglobulin as a Biomarker in Peripheral Arterial Disease: Proteomic Profiling and Clinical Studies Circulation, September 18, 2007; 116(12): 1396 - 1403. [Abstract] [Full Text] [PDF]

				A. M. Wilson, R. Harada, N. Nair, N. Balasubramanian, and J. P. Cooke L-Arginine Supplementation in Peripheral Arterial Disease: No Benefit and Possible Harm Circulation, July 10, 2007; 116(2): 188 - 195. [Abstract] [Full Text] [PDF]